VXL — Vaxil Bio Cashflow Statement
0.000.00%
- CA$1.37m
- CA$0.45m
- 33
- 40
- 40
- 31
Annual cashflow statement for Vaxil Bio, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -1.15 | -1.36 | -0.986 | -0.584 | -0.254 |
Depreciation | |||||
Non-Cash Items | 0.151 | 0.161 | 0.07 | 0.017 | 0.02 |
Other Non-Cash Items | |||||
Changes in Working Capital | 0.307 | 0.037 | -0.193 | -0.169 | -0.327 |
Change in Accounts Receivable | |||||
Change in Accounts Payable | |||||
Change in Payable / Accrued Expenses | |||||
Cash from Operating Activities | -0.596 | -1.1 | -1.08 | -0.734 | -0.561 |
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -0.068 | 2.56 | 1.81 | 0 | — |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -0.67 | 1.43 | 0.731 | -0.731 | -0.572 |